Lentitek

Lentitek develops proprietary manufacturing technology designed to enhance the quality and yield of lentiviral vectors used in advanced therapy medicinal products (ATMPs). The company's method utilizes a novel promoter to reduce vector genome splicing and payload breakthrough expression, supporting applications such as in-vivo CAR-T and armoured CARs. Their solution is designed to integrate into existing production workflows, including transient transfection and stable cell line production, for developers of cell and gene therapies.